Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13258290 | 0.91 | MAPT (0.66) | L3MBTL1TP53NPSR1POLBSMN1; SMN2 | |
| SCHEMBL15766067 | 0.79 | TGM2 (0.59) | POLBSMN1; SMN2LMNAALDH1A1GAA | |
| SCHEMBL943551 | 0.79 | L3MBTL1 (0.71) | L3MBTL1TP53NPSR1SMN1; SMN2MAPT | |
| SCHEMBL17068754 | 0.79 | L3MBTL1 (1.00) | L3MBTL1NPSR1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL17109045 | 0.78 | KMT2A (0.73) | L3MBTL1TP53NPSR1POLBMAPT | |
| SCHEMBL7763084 | 0.77 | POLB (0.64) | POLBSMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL17109046 | 0.76 | NPSR1 (0.68) | L3MBTL1NPSR1POLBMAPTLMNA | |
| SCHEMBL15766059 | 0.76 | CA2 (0.70) | NPSR1POLBLMNAALDH1A1GAA | |
| SCHEMBL8368585 | 0.76 | L3MBTL1 (0.64) | L3MBTL1NPSR1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17913889 | 0.75 | ALDH1A1 (0.79) | L3MBTL1NPSR1POLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083819-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20150265608-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150265608-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2010096830-A2 | METHOD TO TREAT PSORIASIS AND OTHER HYPERPROLIFERATIVE SKIN DISORDERS | CORNELL UNIVERSITY (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2009143178-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008064342-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | L3MBTL1 2632/4885TP53 3634/4885NPSR1 153/4885 |
| US-20150265608-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | ARHGEF2, ARHGDIB, ARHGDIA | L3MBTL1 626/4885TP53 1888/4885NPSR1 4509/4885 |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | L3MBTL1 2586/4885TP53 3598/4885NPSR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.